RT @norbertkraut1: Thanks for including our paper published in @CD_AACR describing BI-3406, a potent and selective SOS1-KRAS interaction in…
RT @norbertkraut1: Thanks for including our paper published in @CD_AACR describing BI-3406, a potent and selective SOS1-KRAS interaction in…
RT @norbertkraut1: Thanks for including our paper published in @CD_AACR describing BI-3406, a potent and selective SOS1-KRAS interaction in…
RT @norbertkraut1: Thanks for including our paper published in @CD_AACR describing BI-3406, a potent and selective SOS1-KRAS interaction in…
Thanks for including our paper published in @CD_AACR describing BI-3406, a potent and selective SOS1-KRAS interaction inhibitor. https://t.co/s46WdvY3cm @MarcoHHofmann @D_B_McConnell @Real_Dr_Kessler @gerlach_d @timheff5 #KRAS #AACR23
RT @gerlach_d: Curious about SOS1 as a cancer target? Read the @CD_AACR paper here https://t.co/L8cYltrWw8, look at opnMe https://t.co/1XVF…
RT @gerlach_d: Curious about SOS1 as a cancer target? Read the @CD_AACR paper here https://t.co/L8cYltrWw8, look at opnMe https://t.co/1XVF…
RT @gerlach_d: Curious about SOS1 as a cancer target? Read the @CD_AACR paper here https://t.co/L8cYltrWw8, look at opnMe https://t.co/1XVF…
RT @gerlach_d: Curious about SOS1 as a cancer target? Read the @CD_AACR paper here https://t.co/L8cYltrWw8, look at opnMe https://t.co/1XVF…
RT @gerlach_d: Curious about SOS1 as a cancer target? Read the @CD_AACR paper here https://t.co/L8cYltrWw8, look at opnMe https://t.co/1XVF…
Curious about SOS1 as a cancer target? Read the @CD_AACR paper here https://t.co/L8cYltrWw8, look at opnMe https://t.co/1XVFyNQq29 and explore our data, on how a SOS1 inhibitor can overcome KRAS G12C resistance by @MarcoHHofmann et al. https://t.co/Nqzl3h
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined ... https://t.co/FOtjiyLGXY
BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined ... https://t.co/FOtjiyLGXY
RT @gerlach_d: While waiting for the #Targets21 Session 5: "Drugging Difficult Targets" with highlights on #KRAS I recall my last in-person…
RT @gerlach_d: While waiting for the #Targets21 Session 5: "Drugging Difficult Targets" with highlights on #KRAS I recall my last in-person…
コロナ禍でこの盛況ぶり、さすがKRAS
RT @gerlach_d: While waiting for the #Targets21 Session 5: "Drugging Difficult Targets" with highlights on #KRAS I recall my last in-person…
RT @gerlach_d: While waiting for the #Targets21 Session 5: "Drugging Difficult Targets" with highlights on #KRAS I recall my last in-person…
RT @gerlach_d: While waiting for the #Targets21 Session 5: "Drugging Difficult Targets" with highlights on #KRAS I recall my last in-person…
RT @gerlach_d: While waiting for the #Targets21 Session 5: "Drugging Difficult Targets" with highlights on #KRAS I recall my last in-person…
While waiting for the #Targets21 Session 5: "Drugging Difficult Targets" with highlights on #KRAS I recall my last in-person #Targets19 meeting with @MarcoHHofmann, @norbertkraut1, @timheff5 and others. Our work on the SOS1::KRASi has been published https:
RT @Real_Dr_Kessler: Do not miss our publications on BI-3406 when you order on opnMe: https://t.co/rDJ4ixNZRd and https://t.co/m4dMVbIafg
RT @Real_Dr_Kessler: Do not miss our publications on BI-3406 when you order on opnMe: https://t.co/rDJ4ixNZRd and https://t.co/m4dMVbIafg
RT @Real_Dr_Kessler: Do not miss our publications on BI-3406 when you order on opnMe: https://t.co/rDJ4ixNZRd and https://t.co/m4dMVbIafg
Do not miss our publications on BI-3406 when you order on opnMe: https://t.co/rDJ4ixNZRd and https://t.co/m4dMVbIafg
BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined ... https://t.co/FOtjiyLGXY
RT @imsmd: @D_B_McConnell @Boehringer listed a number of KRAS-specific inhibitors, including SOS1-KRAS interaction inhibitors (BI-3406 publ…
@D_B_McConnell @Boehringer listed a number of KRAS-specific inhibitors, including SOS1-KRAS interaction inhibitors (BI-3406 published here: https://t.co/JEl4osdMPj) #RASSymposium21
RT @ElizSMcKenna: Pan-KRAS approaches that would inhibit mutant #KRAS in an allele-independent manner are being discussed, like targeting t…
Pan-KRAS approaches that would inhibit mutant #KRAS in an allele-independent manner are being discussed, like targeting the KRAS-SOS1 interaction alone and in combo with MEK inhibition as in this paper #AACR21 https://t.co/H48xFIR77g
RT @ElizSMcKenna: Other approaches for drugging #KRAS have emerged, like targeting the interaction between KRAS and SOS1 as a pan-KRAS ther…
Other approaches for drugging #KRAS have emerged, like targeting the interaction between KRAS and SOS1 as a pan-KRAS therapy, an approach reported recently in @CD_AACR and discussed further at #AACR21 @MarcoHHofmann @norbertkraut1 @Boehringer /5 https://t.
@MDollares @JacobPlieth BI 1701963 is based on a collaboration with $FMTX but fully optimized and developed internally similar to BI-3406. https://t.co/UC7E1FaPVL ; https://t.co/rDJ4ixNZRd
RT @CD_AACR: From the January issue: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers…
RT @CD_AACR: From the January issue: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers…
RT @CD_AACR: From the January issue: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers…
RT @CD_AACR: From the January issue: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers…
RT @CD_AACR: From the January issue: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers…
RT @CD_AACR: From the January issue: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers…
RT @CD_AACR: From the January issue: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers…
RT @CD_AACR: From the January issue: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers…
RT @CD_AACR: From the January issue: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers…
RT @CD_AACR: From the January issue: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers…
RT @CD_AACR: From the January issue: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers…
From the January issue: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined #MEK inhibition. @MarcoHHofmann @norbertkraut1 @Boehringer #DrugDevelopment https://t.co/uAb7JKPKlY https://t.c
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
おー
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
RT @gerlach_d: Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now publi…
Our work on a novel small-molecule drug, the SOS1::KRAS inhibitor BI-3406, which targets KRAS-addicted cancers, is now published & formatted in the January 2021 issue of Cancer Discovery @CD_AACR - https://t.co/JtwNf5wMXS @MarcoHHofmann @norbertkraut1
RT @MarcoHHofmann: Our SOS1::KRAS inhibitor BI-3406 manuscript got published @CD_AACR:Combining SOS1::KRAS and MEK inhibition provides an a…
RT @CD_AACR: Marco H. Hofmann is speaking about his article: A10 BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effec…
RT @CD_AACR: Marco H. Hofmann is speaking about his article: A10 BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effec…
RT @ElizSMcKenna: Read the @CD_AACR paper related to @MarcoHHofmann’s talk at #ENASymp #ENASymp20
SOS1::KRAS & KRASG12C inhibitors
Read the @CD_AACR paper related to @MarcoHHofmann’s talk at #ENASymp #ENASymp20
RT @CD_AACR: Marco H. Hofmann is speaking about his article: A10 BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effec…
RT @gerlach_d: @MarcoHHofmann @Boehringer @MDAndersonNews @timheff5 More details in the SOS1::KRAS paper: https://t.co/mzPaVte4A0 #ENASymp
RT @gerlach_d: @MarcoHHofmann @Boehringer @MDAndersonNews @timheff5 More details in the SOS1::KRAS paper: https://t.co/mzPaVte4A0 #ENASymp
RT @CD_AACR: Marco H. Hofmann is speaking about his article: A10 BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effec…
@MarcoHHofmann @Boehringer @MDAndersonNews @timheff5 More details in the SOS1::KRAS paper: https://t.co/mzPaVte4A0 #ENASymp
RT @CD_AACR: Marco H. Hofmann is speaking about his article: A10 BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effec…
Marco H. Hofmann is speaking about his article: A10 BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined #MEK inhibition. @norbertkraut1 @Boehringer #DrugDevelopment #ENASymp https://t.co
RT @oncologician: @DrShubhamPant @GIcancerDoc @Aiims1742 This was the most exciting paper I read last week.Such huge potential for translat…
RT @VivekSubbiah: BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined ME…
RT @VivekSubbiah: BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined ME…
RT @VivekSubbiah: BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined ME…
RT @CD_AACR: #ICYMI: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined…
RT @CD_AACR: #ICYMI: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined…
RT @CD_AACR: #ICYMI: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined…
#ICYMI: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined #MEK inhibition. @MarcoHHofmann @norbertkraut1 #ESMO20 https://t.co/zDD5j95sCp https://t.co/wPJujW62d3
RT @VivekSubbiah: BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined ME…
BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition @CD_AACR https://t.co/bB7rYbkFuX
RT @oncologician: @DrShubhamPant @GIcancerDoc @Aiims1742 This was the most exciting paper I read last week.Such huge potential for translat…
RT @oncologician: @DrShubhamPant @GIcancerDoc @Aiims1742 This was the most exciting paper I read last week.Such huge potential for translat…
RT @CD_AACR: ICYMI: BI-3406, a potent and selective SOS1–KRAS-interaction inhibitor, is effective in #KRAS-driven cancers through combined…
RT @D_B_McConnell: KRAS, the beating heart of cancer, like a normal heart needs a pacemaker to beat. SOS1 is KRAS´ pacemaker. Our SOS1 in…
RT @oncologician: @DrShubhamPant @GIcancerDoc @Aiims1742 This was the most exciting paper I read last week.Such huge potential for translat…
RT @oncologician: @DrShubhamPant @GIcancerDoc @Aiims1742 This was the most exciting paper I read last week.Such huge potential for translat…
RT @oncologician: @DrShubhamPant @GIcancerDoc @Aiims1742 This was the most exciting paper I read last week.Such huge potential for translat…
RT @oncologician: @DrShubhamPant @GIcancerDoc @Aiims1742 This was the most exciting paper I read last week.Such huge potential for translat…
RT @oncologician: @DrShubhamPant @GIcancerDoc @Aiims1742 This was the most exciting paper I read last week.Such huge potential for translat…